Sugi Predict

Sugi Predict / Compounds / SCHEMBL7779200

SCHEMBL7779200

SCHEMBL7779200

O=C(CBr)c1ccc(Cl)cc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.52
▸ FLT1 P17948 2/20 0.47
▸ FLT4 P35916 2/20 0.47
▸ KDR P35968 2/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ TSHR P16473 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ERCC5 P28715 2/20 0.42
▸ FEN1 P39748 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ LMNA P02545 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ GPR27 Q9NS67 1/20 0.39
▸ GRIK1 P39086 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702134 1.00 GSK3B (0.52) GSK3BFLT1FLT4KDRALDH1A1
SCHEMBL20364210 0.83 FLT1 (0.46) GSK3BFLT1FLT4KDRALDH1A1
SCHEMBL29444021 0.83 ALDH1A1 (0.49) FLT1FLT4KDRALDH1A1MAPK1
SCHEMBL2870299 0.83 ALDH1A1 (0.49) FLT1FLT4KDRALDH1A1MAPK1
SCHEMBL29859075 0.82 ALDH1A1 (0.69) GSK3BALDH1A1MAPK1HIF1ATSHR
SCHEMBL641759 0.82 ALDH1A1 (0.69) GSK3BALDH1A1MAPK1HIF1ATSHR
Hydrochloric Acid SCHEMBL30702158 0.81 FLT1 (0.45) FLT1FLT4KDRALDH1A1MAPK1
Hydrochloric Acid SCHEMBL20360200 0.81 FLT1 (0.45) FLT1FLT4KDRALDH1A1MAPK1
SCHEMBL10159191 0.81 GSK3B (0.52) GSK3BALDH1A1MAPK1HIF1ATSHR
SCHEMBL11707304 0.80 FLT1 (0.44) GSK3BFLT1FLT4KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-09-11 — — US disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 — — US disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 — — US disclosed
EP-3180317-B1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME (US) 2021-04-14 — — EP disclosed
EP-3319956-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2021-01-06 — — EP disclosed
EP-3319956-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2021-01-06 — — EP disclosed
US-10421742-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-09-24 — — US disclosed
US-10421742-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-09-24 — — US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
US-9868727-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2018-01-16 — — US disclosed
US-20170210732-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-27 — — US disclosed
EP-3180317-A1 FACTOR XIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-06-21 — — EP disclosed
WO-2016015593-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-02-04 — — WO disclosed
EP-0735142-B1 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICALS CO LTD (JP) 2001-10-24 — — EP disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 — — US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421742-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO GSK3B 2484/4885FLT1 103/4885FLT4 104/4885
US-11180471-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO GSK3B 2484/4885FLT1 103/4885FLT4 104/4885
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO GSK3B 2484/4885FLT1 103/4885FLT4 104/4885
US-20170210732-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI GSK3B 352/4885FLT1 268/4885FLT4 617/4885
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO GSK3B 2484/4885FLT1 103/4885FLT4 104/4885
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO GSK3B 2484/4885FLT1 103/4885FLT4 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.